Table 4 Comparison of methylated HYP2 levels and MoM values between controls and patients with preeclampsia with or without SGA neonates.

From: Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction

 

Controls

Preeclampsia

P†

Pa‡

Pb‡

Pc‡

SGA ( +)

SGA ( −)

2nd trimester

(n = 78)

(n = 11)

(n = 18)

    

Copies/mL

9,441

(5,878–12,251)

18,503

(10,964–38,959)

9,643

(4,629–12,349)

0.007

0.008

0.69

0.032

MoM

0.998

(0.952–1.026)

1.077

(1.015–1.140)

0.995

(0.909–1.036)

0.008

0.009

0.62

0.034

3rd trimester

(n = 58)

(n = 8)

(n = 12)

    

Copies/mL

14,969

(11,411–21,873)

68,092

(51,688–103,911)

47,160

(28,833–87,854)

 < .0001

 < .0001

 < .001

0.27

MoM

0.979

(0.948–1.029)

1.086

(1.075–1.116)

1.114

(1.017–1.181)

 < .0001

0.002

0.001

0.85

  1. Data are given as median (interquartile range).
  2. Pa, PE with SGA versus controls; Pb, PE without SGA versus controls; Pc, PE with SGA versus PE without SGA.
  3. MoM multiple of the median, SGA small for gestational age.
  4. †P value by the Kruskal–Wallis test.
  5. ‡P value by the Wilcoxon rank sum test (adjusted by the step-up Bonferroni method).
Back to article page